28165-50-6

Basic information

• Product Name: 2-Amino-6-bromophenol
• Synonyms: 3-BROMO-2-HYDROXYANILINE;2-AMINO-6-BROMOPHENOL;2-AMINO-6-BROMOPHENOL-97%;2-Amino-6-bromophenol ,98%;2-Amino-6-bromopheno;Phenol, 2-aMino-6-broMo-
• CAS NO: 28165-50-6
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• Mol File: 28165-50-6.mol
• Article Data: 22

Chemical Properties

• Melting Point: 83-84°C
• Boiling Point: 246.354 °C at 760 mmHg
• Flash Point: 102.792 °C
• Appearance: /
• Density: 1.768 g/cm³
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 8.22±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-6-bromophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-6-bromophenol(28165-50-6)
• EPA Substance Registry System: 2-Amino-6-bromophenol(28165-50-6)

Safety Data

• Hazard Codes: Xi,N,Xn
• Statements: 22-50/53
• Safety Statements: 60-61
• Hazardous Substances Data: 28165-50-6(Hazardous Substances Data)

Usage

Chemical Properties

Gray pwoder

InChI:InChI=1/C6H6BrNO/c7-4-2-1-3-5(8)6(4)9/h1-3,9H,8H2

Upstream product

• 88-75-5 2-hydroxynitrobenzene 
• 13073-25-1 2-bromo-6-nitro-phenol 
• 107986-35-6 N-(3-bromophenyl)-O-pivaloylhydroxylamine 
• 91631-57-1 N-(sulfonatooxy)-3-bromoacetanilide 

Downstream Products

• 1013643-01-0 1-(3-bromo-2-hydroxy-phenyl)-3-(3,4,5-trimethoxyphenyl)-thiourea 
• 688363-73-7 8-bromo-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1013643-09-8 7-bromobenzo[d]oxazole-2(3H)-thione 
• 863723-87-9 C₂₂H₁₈N₂O₃ 
• 871367-14-5 7-bromo-1,3-benzoxazol-2(3H)-one 
• 956832-29-4 2-(2-amino-6-bromophenoxy)-1-(3-trifluoromethoxyphenyl)ethanone 
• 956832-59-0 2-(2-amino-6-bromophenoxy)-1-(4-trifluoromethoxyphenyl)ethanone 
• 956831-52-0 2-(2-amino-6-bromophenoxy)-1-(3-ethoxyphenyl)ethanone 
• 956832-54-5 2-(2-amino-6-bromophenoxy)-1-phenylethanone 
• 956832-67-0 2-(2-amino-6-bromophenoxy)-1-(3-chlorophenyl)ethanone 

Relevant articles and documents

Synthesis method of eltrombopag olamine

The invention discloses a synthesis method of eltrombopag olamine, belonging to the technical field of synthesis methods of compounds. According to the synthesis method, 2-bromo-6-nitrophenol is takenas a raw material, and the nitro group is reduced to th

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

Comprehensive Analysis of Structure-Activity Relationships of α-Ketoheterocycles as sn-1-Diacylglycerol Lipase α Inhibitors

Diacylglycerol lipase α (DAGLα) is responsible for the formation of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the central nervous system. DAGLα inhibitors are required to study the physiological role of 2-AG. Previously, we identified the α-ketoheterocycles as potent and highly selective DAGLα inhibitors. Here, we present the first comprehensive structure-activity relationship study of α-ketoheterocycles as DAGLα inhibitors. Our findings indicate that the active site of DAGLα is remarkably sensitive to the type of heterocyclic scaffold with oxazolo-4N-pyridines as the most active framework. We uncovered a fundamental substituent effect in which electron-withdrawing meta-oxazole substituents increased inhibitor potency. (C6-C9)-acyl chains with a distal phenyl group proved to be the most potent inhibitors. The integrated SAR data was consistent with the proposed binding pose in a DAGLα homology model. Altogether, our results may guide the design of future DAGLα inhibitors as leads for molecular therapies to treat neuroinflammation, obesity, and related metabolic disorders.